LifeMD partners with Lilly to dispense and ship self-pay GLP-1 medicines nationwide

By Public Technologies
  • LifeMD entered an arrangement with Eli Lilly to dispense and ship Lilly’s self-pay GLP-1 medicines directly to eligible patients nationwide.
  • The program includes Zepbound and Foundayo at Lilly’s established self-pay prices, with prescriptions fulfilled through the affiliated mail-order pharmacy.
  • Access requires an independent clinical evaluation through the virtual care platform; medications are cash-pay only, with no insurance billing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LifeMD Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050730PRIMZONEFULLFEED9870922) on November 05, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.